
Turkesterone Powder Men Health Supplements Ajuga Turkestanica Extract
Phone Number : 86-15209233790
WhatsApp : +8615209233790
Detail Information |
|||
Product Name: | Sildenafil | Appearance: | White Crystalline Powder |
---|---|---|---|
CAS No.: | 139755-83-2 | EINECS No.: | 252-082-4 |
Specification: | 99% | Molecular Formula: | C22H30N6O4S |
Molecular Weight: | 474.57600 | Shelf Life: | 2 Years |
Test Method: | HPLC | Storage: | Cool Dry Place |
Highlight: | 1.39 g/cm3 male sexual enhancement,Male Sexual Enhancement 99% Sildenafil,139755-83-2 Sildenafil Citrate Powder |
Product Description
Le-nutra Top Grade male sexual enhancement 99% CAS 139755-83-2 sildenafil citrate powder
Base information of Product
Product Name | Sildenafil |
Appearance | White crystalline powder |
Cas No. | 139755-83-2 |
Active ingredients | 99% |
Shelf Life | 2 years |
Introduction of Product
Sildenafil is a white crystalline powder with the molecular formula C22H30N6O4s and a density of 1.39g/cm3. Sildenafil is a drug for erectile dysfunction that was accidentally invented during the development of drugs for cardiovascular diseases. It is commonly known by its trade name Viagra. But Viagra, the generic name for sildenafil in China, is more widely used and influential than its commercial name.
Function and Application of Product
1. Sildenafil is a selective inhibitor of phosphodiesterase (PDE)V, which can enhance the physiological response of penile erection caused by NO release during sexual stimulation. Mainly used for penile erectile dysfunction.
2. In addition to human cavernous smooth muscle, low concentrations of PDE5 were also found in platelets, blood vessels, visceral smooth muscle and skeletal muscle. Sildenafil may enhance antiplatelet aggregation (in vitro), inhibition of platelet thrombosis (in vivo), and peripheral vasodilation by inhibiting PDE5 in these tissues.
The developing history of Sildenafil
Sildenafil be developed by Pfizer, it was first introduced as a 5-phosphodiesterase inhibitor for the treatment of cardiovascular disease. The researchers hope sildenafil will dilate blood vessels and alleviate cardiovascular disease by releasing the biologically active nitric oxide, which relaxes cardiovascular smooth muscle. However, clinical studies have shown that sildenafil is not as effective as expected. As a cardiovascular drug, sildenafil has shown disappointing performance and has not been able to grow into a successful treatment. In April 1991, a clinical trial of sildenafil officially failed, but a side effect reported by subjects caught researchers' attention. The researchers found that patients who had been tested were reluctant to hand over the remaining drugs. When tracked down, the drug was found to improve the patients' sex lives. Sildenafil's effects on the cavernous muscle of the penis were studied with the approval of Pfizer executives, and on March 27, 1998, the FDA approved the product, making it one of Pfizer's best-known products.
Enter Your Message